Clincosm LogoSign in Get a demo

The Absorption, Metabolism and Excretion of [14C]Ensartinib in Human

Sponsor
Betta Pharmaceuticals Co., Ltd. (Industry)
Overall Status
Unknown status
CT.gov ID
NCT03804541
Collaborator
(none)
6
Enrollment
1
Location
1
Arm
9.1
Anticipated Duration (Months)
0.7
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This is a single-center, open-label, single-dose phase I study to investigate the absorption, metabolism and excretion of [14C] Ensartinib in healthy Chinese male subjects. The study will be conducted into two steps：Firstly, 2 subjects are enrolled in to participate in the pilot study to grope for the completion date of plasma, urine and feces sampling on the 3rd day post-dose and onwards. Then, the collection time of blood and excreta samples (urine and feces) from the subsequent 4-6 subjects will be adjusted according to the pilot study.

Condition or Disease Intervention/Treatment Phase
Phase 1

Detailed Description

Subjects who had signed informed consent and meet inclusion criteria and no exclusion criteria are admitted to Phase I Clinical Unit two days prior to dosing (D-2). On the morning of Day 1 before dosing, subjects will be transferred to nuclear medical ward. And after an overnight fast of at least 10 h, subjects will receive a single oral dose of 200 mg (100 μCi) of [14C]Ensartinib as an oral suspension. Then, after two days of the dosing, subjects will be transferred back to Phase I Clinical Unit ward and confined to this unit until blood or excreta sampling and safety monitoring at the designated time points or intervals are complete

Study Design

Study Type:
Interventional
Anticipated Enrollment :
6 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A Single-center, Open-label, Single-dose Phase I Study to Investigate the Absorption, Metabolism and Excretion of [14C]Ensartinib (X-396) After a Single Oral 200mg (100µCi) Dose in Healthy Chinese Male Subjects
Actual Study Start Date :
Dec 28, 2018
Anticipated Primary Completion Date :
Jun 1, 2019
Anticipated Study Completion Date :
Oct 1, 2019

Arms and Interventions

Arm Intervention/Treatment
Experimental: [14C]Ensartinib

To investigate the absorption properties, as well as to evaluate the mass balance and elucidate the pathways of biotransformation after a single oral dose (200mg, 100µCi) of [14C]Ensartinib to healthy Chinese male subjects。

Drug: Ensartinib
A novel, potent ALK inhibitor.The ALK inhibitor ensartinib has been validated in potency and selectivity assays indicating that it is more selective and up to 10 times more potent than competitive ALK inhibitors. Ensartinib has been active in animal models of non-small cell lung cancer (NSCLC) and neuroblastoma, a childhood cancer. Importantly, ensartinib has shown activity in models with ALK mutations that confer resistance to other small molecule ALK inhibitors.
Other Names:
  • X-396

    		•

    Outcome Measures

    Primary Outcome Measures

    1. Radioactivity concentration of each plasma sample [Day1-Day15]

      Use liquid scintillation counter to evaluate Radioactivity concentration of each plasma（DPM/ml) sample

    2. Radioactivity concentration of each urine samples [Day1-Day15]

      Use liquid scintillation counter to evaluate Radioactivity concentration of each urine（DPM/ml） sample

    3. Radioactivity concentration of each feces sample [Day1-Day15]

      Use liquid scintillation counter to evaluate Radioactivity concentration of each feces（DPM/g） sample

    4. Total recovery of radioactivity in urine and feces [Day1-Day15]

      Calculate the total radioactivity in urine and feces based on the radioactivity concentration of each sample.

    Secondary Outcome Measures

    1. Plasma drug concentrations [Day1-Day15]

      To determine the plasma concentrations of Ensartinib with validated LC-MS/MS method for obtaining its pharmacokinetics parameters;

    2. Number of participants with treatment-related adverse events as assessed by CTCAE v4.03 [Day1-Day15]

      According to CTCAE v4.03, the number and frequency of adverse events after a single dose of test drug were assessed.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 50 Years
    Sexes Eligible for Study:
    Male
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    A subject will be eligible for study participation if he meets the following criteria:

    1. healthy male volunteers between the ages of 18 to 50 years old, inclusive;

    2. Body weight >=50 kg, Body mass index (body weight(kg)/hight2(m2)) between 19 and 26 kg/m2 (inclusive);

    3. Normal physical findings, clinical laboratory values, vital signs and 12-lead ECG, or any abnormality that is non-clinically significant;

    4. Male subjects of reproductive potential with partners will be instructed to, and must be willing to practice a highly effective method of birth control for the duration of the study and continuing 1 year after discontinuing treatment with the investigational product. Highly effective methods of birth control include using condom, contraceptive sponge, contraceptive gel, contraceptive film, intrauterine device, oral or injectable contraceptive pill, hypodermic implants or others;

    5. Must understand, and voluntarily sign the informed consent, comply with the requirements of the study

    Exclusion Criteria:

    A subject will not be eligible for study participation if he meets any of the exclusion criteria:

    1. History of or current clinically significant cardio, pulmonary, endocrine, metabolism, renal, hepatic, gastrointestinal, dermatology, infection, hematology, neurological, mental disease or disorder;

    2. Positive test for HBsAg, HBeAg, anti-HCV, anti-HIV or syphilis antibody;

    3. History of clinically significant disease or infection within 1 month before entering the study;

    4. Abnormality in blood pressure, including hypertensive BP (SBP>=140 mmHg, or DBP >=90 mmHg), or hypotensive BP(SBP<90 mmHg, or DBP <=55 mmHg), Pulse rate<55 bpm or >100 bpm;

    5. Long-QT syndrome or family history of it, or QTcB interval > 450 ms; intraventricular blocks or left/right bundle branch block or QRS>120ms; frequent ventricular ectopic beats (any 10s ECG ventricular premature beat >= 1 in screening period); or abnormal resting heart rate (> 100 bpm)

    6. The following abnormal clinical laboratory values

    7. HGB < LLN, and is judged as clinically significant by the investigator；

    8. Abnormal ALP, ALB,TP,CRE,ALT,AST,BIL,BUN, GLU value, and is judged as clinically significant by the investigator;

    9. Received any drug within 14 days before taking the investigational drug, including any prescription drug, OTC drug or herbal drug, except for vitamins and paracetamol;

    10. History of or current swallowing disorder, active gastrointestinal diseases, or other diseases that significantly affect absorption, distribution, metabolism and excretion of drugs;

    11. Chronic constipation or diarrhea, irritable bowel syndrome, inflammatory bowel disease;

    12. Hemorrhoids or perianal disease with regular/perianal bleeding;

    13. Allergies, have allergies to two or more drugs or foods; or have known allergies to the components of the drug (microcrystalline cellulose, stearic acid, hydroxypropyl methylcellulose);

    14. Have donated 500ml or more of blood or plasma 2 months prior to the study drug administration, or more than 50ml within 2 weeks prior to administration;

    15. Vaccination was administered within 6 months prior to screening or during screening;

    16. History of drug or alcohol abuse;

    17. Smoking (> 10 cigarette / day), drinking (> 15 g, pure alcohol / day, equivalent to 450 ml beer, 150 ml wine or 50 ml low-alcohol liquor), or abusing drugs(MOP, METmAMP, MTD, THC, AMP positive) within last 3 months;

    18. Subject with mentally ill and could not understand the property, scope and possible consequences of the study;

    19. subject in prison or whose freedom is restricted by administrative or legal issues;

    20. Failure to comply with clinical study protocols, such as non-cooperation, follow-up visit and completion of entire study;

    21. Investigator, pharmacist, CRC or research associate;

    22. Investigators think that subjects are not suitable to participate in the study;

    23. Subjects who have participated in radiolabeled clinical study prior to drug administration;

    24. Significant radiation exposure within one year prior to drug administration (more than one exposure from chest X-ray, CT scan, or barium meal examination and radiation-related occupations).

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Jiangsu Province Hospital Affiliated to Nanjing Madical University of Medicine Nanjing Jiangsu Provence China 210005

    Sponsors and Collaborators

    • Betta Pharmaceuticals Co., Ltd.

    Investigators

    • Principal Investigator: Feng Shao, Jiangsu Province Hospital Affiliated to Nanjing Madical University of Medicine

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    Responsible Party:
    Betta Pharmaceuticals Co., Ltd.
    ClinicalTrials.gov Identifier:
    NCT03804541
    Other Study ID Numbers:
    • BTP-44316
    First Posted:
    Jan 15, 2019
    Last Update Posted:
    Jan 15, 2019
    Last Verified:
    Jan 1, 2019
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    Yes
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:
    Ensartinib

    Study Results

    No Results Posted as of Jan 15, 2019